This is the beginning of a long journey.
Now that the parliament has proposed its amendments to the EU pharmaceutical framework, member states through the Council of the...
Changes ahead for EU pharma reform
It will be a long and winding road.
Listen to this article
Technical discussions on the EU pharmaceutical legislative reform are underway at the Council of the EU.
Learn what's happening at the US FDA. On the go.
More from EU Pharma Legislation Reform
• By
Technical discussions on the EU pharmaceutical legislative reform are underway at the Council of the EU.
• By
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
• By
In this final article in a series on the ongoing amendments to the pharmaceutical reform package, the Pink Sheet looks at the tougher environmental risk assessment requirements that pharma companies are likely to face in the not-too-distant future.
• By
A number of legislative proposals will be coming under scrutiny at the newly constituted European Parliament in the coming months, including the pharma reform package and draft legislation on EU-level compulsory licensing and “unitary” supplementary protection certificates.